Reuters logo
BRIEF-Beigene presents preliminary phase 1 data for BGB-A317 in multiple solid tumors at ESMO 2017 Congress
September 11, 2017 / 7:11 AM / 13 days ago

BRIEF-Beigene presents preliminary phase 1 data for BGB-A317 in multiple solid tumors at ESMO 2017 Congress

Sept 11 (Reuters) - Beigene Ltd

* Beigene presents preliminary phase 1 data for BGB-A317 in multiple solid tumors at the ESMO 2017 Congress

* Preliminary phase 1 data suggest that BGB-A317 was generally well tolerated

* BGB-A317 exhibited preliminary evidence of anti-tumor activity in advanced patients with each of these tumor types. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below